Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 14/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19555951 | 0.94 | ATF4 (0.45) | ATF4 | |
| SCHEMBL19556229 | 0.94 | ATF4 (0.45) | ATF4 | |
| SCHEMBL19556219 | 0.94 | ATF4 (0.37) | ATF4ALDH1A1HPGDTSHRMAPT | |
| SCHEMBL22437035 | 0.94 | ATF4 (0.37) | ATF4ALDH1A1HPGDTSHRMAPT | |
| SCHEMBL22627874 | 0.93 | ATF4 (0.36) | ATF4BDKRB1ALDH1A1HPGDTSHR | |
| SCHEMBL32689700 | 0.93 | ATF4 (0.36) | ATF4BDKRB1ALDH1A1HPGDTSHR | |
| SCHEMBL22628519 | 0.92 | ATF4 (0.47) | ATF4TSHRNPC1MAPT | |
| SCHEMBL22628079 | 0.91 | SENP2 (0.44) | ATF4ALDH1A1TSHRNPC1MAPT | |
| SCHEMBL32689691 | 0.91 | SENP2 (0.44) | ATF4ALDH1A1TSHRNPC1MAPT | |
| SCHEMBL22628059 | 0.90 | FKBP1A (0.38) | ATF4ALDH1A1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913727-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913727-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | ATF4 1/4885BDKRB1 2945/4885ALDH1A1 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.